{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":4,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":4,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"180dafccc7cc","filters":{"venue":"memo - Magazine of European Medical Oncology"}},"results":[{"id":"W3140318702","doi":"10.1007/s12254-021-00692-7","title":"ESMO 2020 update: Pancreatic cancer","year":2021,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Medizinische Universität Wien","keywords":"Medicine; Pancreatic cancer; Oncology; Randomized controlled trial; Durvalumab; Regimen; Internal medicine; Gemcitabine; Clinical trial; Chemotherapy; Cancer; Immunotherapy; Pembrolizumab","authors":[{"name":"Elisabeth Bergen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0303082763436609,"gpt":0.3652405864764982,"spread":0.3349323101328373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030722,0.000931459,0.001365315,0.004244692,0.0003572464,0.002684682,0.001315105,0.002152881,0.02385346],"category_scores_gemma":[0.005036658,0.0003701542,0.0007381183,0.003617075,0.0003053871,0.001796645,0.001904817,0.002586646,0.02427165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001469229,"about_ca_system_score_gemma":0.001936268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002123576,"about_ca_topic_score_gemma":0.005572366,"domain_scores_codex":[0.9991972,0.0001509914,0.0001202559,0.00005937166,0.000384569,0.00008755279],"domain_scores_gemma":[0.9970004,0.0005845557,0.0006057082,0.00007920153,0.00114679,0.0005833467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001025663,0.00002060293,0.0002444381,0.001128187,0.00002939621,0.00005688402,0.00001067613,0.0001209965,0.0001509985,0.0005017233,0.7862351,0.2113984],"study_design_scores_gemma":[0.00002106277,0.00003182829,0.000473961,0.0007585249,0.00003056344,0.000159835,0.000006595671,0.00003405883,0.00005976753,0.0001905506,0.9982279,0.000005410564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002555009,0.7058846,0.002464917,0.06890149,0.04954239,0.0002568084,0.03426662,0.002033595,0.1340945],"genre_scores_gemma":[0.01060545,0.6963509,0.006255402,0.05495391,0.05392724,0.000535907,0.08583825,0.0006385563,0.0908944],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02385346,"threshold_uncertainty_score":0.07979774,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409502283","doi":"10.1007/s12254-025-01027-6","title":"EffiXane—Non-interventional study on safety and effectiveness of nab-paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting","year":2025,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Gemcitabine; Paclitaxel; Nab-paclitaxel; Medicine; Oncology; Deoxycytidine; First line; Pharmacology; Internal medicine; Chemotherapy","authors":[{"name":"Magdalena Wojtasik","is_ca":false},{"name":"R. Kuehn","is_ca":false},{"name":"Tobias Gaska","is_ca":false},{"name":"Dietmar Reichert","is_ca":false},{"name":"L. Brinkmann","is_ca":false},{"name":"Reinhard Depenbusch","is_ca":false},{"name":"A. Lueck","is_ca":false},{"name":"Kathrin Borchert","is_ca":false},{"name":"B. Tschechne","is_ca":false},{"name":"Michael Goern","is_ca":false},{"name":"C. Constantin","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0188733947914519,"gpt":0.3504243538497163,"spread":0.3315509590582644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001426092,0.0008060741,0.001418953,0.000608768,0.0003042647,0.0008777806,0.0006393885,0.0009274959,0.004228822],"category_scores_gemma":[0.001185808,0.0003803105,0.001595508,0.0003047766,0.0008798502,0.001090269,0.0003909392,0.002662952,0.0007561399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005959191,"about_ca_system_score_gemma":0.0008150149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005611513,"about_ca_topic_score_gemma":0.0008954915,"domain_scores_codex":[0.9991505,0.0004509861,0.00005568619,0.000158594,0.00007846154,0.0001056826],"domain_scores_gemma":[0.9990388,0.0003133681,0.000159334,0.0001310768,0.00004900743,0.0003084551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8897662,0.04313328,0.003716944,0.000240055,0.0009499803,0.00009619362,0.00007475915,0.0003804185,0.008850978,0.0001555217,0.0005726735,0.05206305],"study_design_scores_gemma":[0.3107936,0.6669068,0.01531555,0.00003332732,0.0009334572,0.0001841088,0.00004302974,0.0006236588,0.002755488,0.0001856712,0.002190614,0.00003478108],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956636,0.00156307,0.0002159874,0.0001153038,0.00007457252,0.0004639133,0.0003571722,0.00003446438,0.001512055],"genre_scores_gemma":[0.9912951,0.001641358,0.0009560203,0.0005727573,0.0003809089,0.0004632309,0.001431931,0.0000245654,0.003234204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004228822,"threshold_uncertainty_score":0.01414686,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4390405183","doi":"10.1007/s12254-023-00945-7","title":"Metastasis-directed therapy: new standard or too early to change paradigm?","year":2023,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Medizinische Universität Wien","keywords":"Medicine; Clinical trial; Tolerability; Context (archaeology); Prostate cancer; Disease; Intensive care medicine; Metastasis; Oncology; Internal medicine; Cancer; Adverse effect","authors":[{"name":"Jakob Klemm","is_ca":false},{"name":"Paweł Rajwa","is_ca":false},{"name":"Marcin Miszczyk","is_ca":false},{"name":"Stephan Brönimann","is_ca":false},{"name":"Ekaterina Laukhtina","is_ca":false},{"name":"Ichiro Tsuboi","is_ca":false},{"name":"Akihiro Matsukawa","is_ca":false},{"name":"Mehdi Kardoust Parizi","is_ca":false},{"name":"Pierre I. Karakiewicz","is_ca":true},{"name":"Shahrokh F. Shariat","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1254608486864779,"gpt":0.398598524580373,"spread":0.2731376758938951,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01422596,0.0006520188,0.002905395,0.001243926,0.0005827162,0.004409514,0.002302437,0.002961436,0.003428525],"category_scores_gemma":[0.01446258,0.000293898,0.001210071,0.001121559,0.003679785,0.008971931,0.001683047,0.008971157,0.001938388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002083581,"about_ca_system_score_gemma":0.005527891,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009653944,"about_ca_topic_score_gemma":0.002370862,"domain_scores_codex":[0.9947175,0.002436291,0.0007854523,0.0006640452,0.001159875,0.0002368645],"domain_scores_gemma":[0.985319,0.009366686,0.001080178,0.0005498723,0.003083847,0.0006003898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006967144,0.0001936777,0.0008919819,0.03560402,0.0005076602,0.0004079408,0.0005471078,0.0006252265,0.001701295,0.0600392,0.08791138,0.8108738],"study_design_scores_gemma":[0.0002198802,0.0006975813,0.0009388559,0.02743646,0.0004679804,0.001133928,0.0007892542,0.0004064252,0.0005776907,0.0612951,0.9059601,0.00007683753],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"commentary","genre_scores_codex":[0.0006261061,0.9062631,0.00203886,0.08263033,0.005830199,0.00003600631,0.00005363657,0.00003833956,0.002483465],"genre_scores_gemma":[0.01144744,0.9134958,0.004362167,0.05659134,0.01212764,0.0001368574,0.000103426,0.00004569746,0.001689538],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.01422596,"threshold_uncertainty_score":0.07523495,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4416771546","doi":"10.1007/s12254-025-01087-8","title":"EGFR-mutated advanced non-small cell lung cancer: new era of systemic therapy towards new standards of care","year":2025,"lang":"en","type":"article","venue":"memo - Magazine of European Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CARE Canada","funders":"","keywords":"Osimertinib; Clinical trial; Lung cancer; Chemotherapy; Standard of care; Systemic therapy","authors":[{"name":"Oliver Illini","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009708134768383999,"gpt":0.3524578201357958,"spread":0.3427496853674118,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001442911,0.0004623962,0.001069219,0.0006533347,0.0002790095,0.001406324,0.0006861881,0.0008487307,0.00186187],"category_scores_gemma":[0.001445657,0.0001217933,0.0005947695,0.0007113388,0.0006360085,0.002095604,0.0008468654,0.002317487,0.0006848667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000947866,"about_ca_system_score_gemma":0.002001712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000532941,"about_ca_topic_score_gemma":0.001448747,"domain_scores_codex":[0.9990751,0.000315072,0.000126344,0.0001033905,0.0003166511,0.00006335347],"domain_scores_gemma":[0.9992554,0.0003447184,0.00009465171,0.00002657842,0.000209315,0.00006929789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009747989,0.00005690748,0.0004107972,0.01027922,0.0001181496,0.0003423588,0.0001895231,0.0005097382,0.002260319,0.01158234,0.06661944,0.9075337],"study_design_scores_gemma":[0.0000257172,0.0001661902,0.0005287495,0.003439059,0.00008420613,0.001024919,0.0000954876,0.0001900621,0.0002949238,0.003849964,0.9902852,0.0000155353],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007177285,0.9861341,0.001678134,0.007154739,0.001423169,0.00001622905,0.00003029119,0.00003849489,0.002807116],"genre_scores_gemma":[0.004701303,0.9856128,0.001766723,0.004722908,0.002087418,0.00003553562,0.00008397957,0.00001268924,0.0009767057],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00186187,"threshold_uncertainty_score":0.007630944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}